title: Effect of perzinfotel and a proprietary phospholipase A(2) inhibitor on kinetic gait and subjective lameness scores in dogs with sodium urate-induced synovitis.
abstract: OBJECTIVE
  To investigate the ability of perzinfotel (an N-methyl-d-aspartate receptor antagonist) and a proprietary phospholipase A(2) (PLA(2)) inhibitor to attenuate lameness in dogs with sodium urate (SU)-induced synovitis.
  
  
  METHODS
  8 adult dogs.
  
  
  METHODS
  A blinded 4-way crossover study was performed. Dogs received perzinfotel (10 mg/kg), a proprietary PLA(2) inhibitor (10 mg/kg), carprofen (4.4 mg/kg; positive control treatment), or no treatment (negative control treatment). On the fourth day after initiation of treatment, synovitis was induced via intra-articular injection of SU 1 hour before administration of the last treatment dose. Ground reaction forces were measured and clinical lameness evaluations were performed before (baseline [time 0]) and 2, 4, 6, 8, 12, and 25 hours after SU injection. There was a 21-day washout period between subsequent treatments. Data were analyzed via repeated-measures ANOVAs.
  
  
  RESULTS
  Peak vertical force (PVF) and vertical impulse (VI) values for negative control and perzinfotel treatments were significantly lower at 2 and 4 hours, compared with baseline values. Values for PVF and VI for the PLA(2) inhibitor and positive control treatments did not differ from baseline values at any time points. Between-treatment comparisons revealed significantly higher PVF and VI values for the positive control treatment than for the negative control and perzinfotel treatments at 2 and 4 hours. Values for VI were higher for PLA(2) inhibitor treatment than for negative control treatment at 2 hours.
  
  
  CONCLUSIONS
  Perzinfotel did not significantly alter SU-induced lameness. The proprietary PLA(2) inhibitor attenuated lameness but not as completely as did carprofen.
authors.affiliation: Department of Small Animal Medicine and Surgery, College of Veterinary Medicine, University of Georgia, Athens, GA 30602, USA. Budsberg@uga.edu
authors.forename: Steven C
authors.initials: SC
authors.lastname: Budsberg
authors.forename: Bryan T
authors.initials: BT
authors.lastname: Torres
authors.forename: Raphael J
authors.initials: RJ
authors.lastname: Zwijnenberg
authors.forename: C Mark
authors.initials: CM
authors.lastname: Eppler
authors.forename: James D
authors.initials: JD
authors.lastname: Clark
authors.forename: Curtis J
authors.initials: CJ
authors.lastname: Cathcart
authors.forename: Lisa R
authors.initials: LR
authors.lastname: Reynolds
authors.forename: Sami
authors.initials: S
authors.lastname: Al-Nadaf
mesh_terms: D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use*; D053961:Azabicyclo Compounds / Q000627:therapeutic use*; D001798:Blood Proteins / Q000627:therapeutic use*; D002227:Carbazoles / Q000494:pharmacology; D018592:Cross-Over Studies; D004283:Dog Diseases / Q000139:chemically induced / Q000188:drug therapy* / Q000473:pathology; D004285:Dogs; D018691:Excitatory Amino Acid Antagonists / Q000627:therapeutic use*; D005260:Female; D005684:Gait; D007700:Kinetics; D007794:Lameness, Animal / Q000139:chemically induced / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D063065:Organophosphonates / Q000627:therapeutic use*; D013585:Synovitis / Q000139:chemically induced / Q000188:drug therapy / Q000473:pathology / Q000662:veterinary*; D014527:Uric Acid
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D053961:Azabicyclo Compounds; D001798:Blood Proteins; D002227:Carbazoles; D018691:Excitatory Amino Acid Antagonists; D063065:Organophosphonates; C400481:PLIalpha; D014527:Uric Acid; C007005:carprofen; C110623:EAA-090